Farxiga Cost in Colorado 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is the Cash Price of Farxiga in Colorado in 2026?

The cash price of Farxiga at Colorado retail pharmacies sits at $620 per month for a 30-tablet supply of dapagliflozin 10 mg in 2026. That figure reflects AstraZeneca's wholesale acquisition cost, which major chains including King Soopers, Walgreens, and CVS pass through to uninsured patients with very little variation.

GoodRx coupons available in Colorado ZIP codes can reduce that price to a range of $480 to $560 at select pharmacies, depending on the dispensing location. Neither figure is trivial, and the price gap between branded Farxiga and compounded dapagliflozin is wider in Colorado than in states where compounding access is restricted.

No FDA-approved generic dapagliflozin existed as of mid-2025. AstraZeneca's compound patent on the SGLT2 mechanism in Farxiga's exact formulation is expected to face its first generic challenge no earlier than 2028. Until a generic enters the market, the $620 list price is the baseline every Colorado patient negotiates against.

For context: the DAPA-HF trial (N=4,744), published in the New England Journal of Medicine in 2019, demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74; 95% CI 0.65, 0.85; P<0.001) [1]. That outcome is what makes the price conversation so clinically significant. Patients who cannot afford $620/month and have no insurance pathway are simply going without a drug that lowers the risk of dying from heart failure.

View the Farxiga FDA prescribing information for the full indication set and dosing table [2].

Does Colorado Medicaid Cover Farxiga?

Colorado Medicaid covers Farxiga for two FDA-approved indications: heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF) and chronic kidney disease (CKD) with albuminuria. It does not cover Farxiga as a standalone glucose-lowering agent for type 2 diabetes when that is the only qualifying diagnosis on the claim.

This is a meaningful distinction. A Colorado Medicaid patient whose chart shows both type 2 diabetes and a CKD diagnosis with a urine albumin-to-creatinine ratio (UACR) above 200 mg/g will qualify. A patient whose chart shows type 2 diabetes without documented cardiac or renal comorbidity will not, regardless of clinical benefit.

Colorado's Preferred Drug List (PDL) categorizes Farxiga as a non-preferred agent for type 2 diabetes, meaning even commercially insured patients on certain managed-care plans may face a prior authorization (PA) requirement. The PA typically asks providers to document failure of or contraindication to at least one preferred SGLT2 inhibitor or metformin.

For Medicaid members who qualify, cost-sharing under Colorado's SoonerCare equivalent is minimal: generally $3 to $8 per fill at an in-network pharmacy. Providers submitting a PA for the HF indication should reference AHA/ACC 2022 guideline language, which states that SGLT2 inhibitors are recommended for "patients with HFrEF to reduce the risk of HF hospitalization and cardiovascular death" with a Class I, Level A designation [3].

Which Private Insurance Plans Cover Farxiga in Colorado?

Major Colorado health plans, including Anthem Blue Cross Blue Shield of Colorado, Cigna, UnitedHealthcare, Aetna, and Kaiser Permanente Colorado, carry Farxiga on their formularies for at least one indication in 2026. Tier placement and out-of-pocket responsibility vary significantly.

Anthem BCBS Colorado: Farxiga sits on Tier 3 (preferred brand) for most commercial plans, meaning patients typically pay $55 to $90 per 30-day fill after meeting their deductible. The AstraZeneca savings card (see below) can reduce this to $0 in many cases.

UnitedHealthcare plans offered through Colorado's exchange (Connect for Health Colorado): Farxiga is Tier 3 on most silver and gold plans. Deductibles range from $1,500 to $4,500 depending on the plan year, which means the first one to three fills of the year may cost full cash price before coverage kicks in.

Cigna Colorado: Prior authorization is required for the HF indication on most Cigna commercial plans. Once approved, member cost-share runs $60 to $100 per month.

Kaiser Permanente Colorado: As an integrated insurer-provider, Kaiser places Farxiga on its Colorado formulary at Tier 3 with a $70 copay. Internal prescribing pathways at Kaiser may differ from outside providers seeking to prescribe to Kaiser-insured patients.

If your plan requires a PA, your prescriber needs to document at minimum: the confirmed diagnosis (HF with documented EF measurement, or CKD with UACR and eGFR), prior therapy history, and the clinical rationale for SGLT2 inhibition. A January 2022 NEJM review by Vaduganathan et al. summarized the combined cardiorenal evidence base across four major SGLT2 inhibitor trials and noted that "the number needed to treat to prevent one primary outcome event ranged from 19 to 28 across trials" [4], which is a concrete figure to include in a PA letter.

How the AstraZeneca Savings Card Works in Colorado

AstraZeneca's AZ&Me savings card and the separate Farxiga commercial copay card are the most direct manufacturer-sponsored discount programs available to Colorado patients.

The commercial copay card applies to patients who have commercial (private) insurance. It does not apply to Medicaid, Medicare Part D, or any other federal payer. Eligible Colorado patients pay as little as $0 per month up to a maximum savings of $150 per 30-day supply. The card is renewable annually and does not require income verification for the commercial version.

The AZ&Me Prescription Savings Program is the income-based program for uninsured or underinsured patients. Eligibility is income-tested, with thresholds adjusted annually. For 2025-2026, patients earning up to 600% of the federal poverty level (roughly $90,000 for a single adult) may qualify for free or steeply reduced-cost Farxiga directly from AstraZeneca. Colorado residents can apply online at AstraZeneca's patient assistance portal or ask their prescriber to submit the application on their behalf.

To use the savings card at a Colorado pharmacy, the patient presents the card (digital or printed) at the pharmacy counter alongside their commercial insurance card. The pharmacy runs the insurance claim first, then applies the manufacturer savings as a secondary adjustment. Net cost after the card is often $0 to $30.

One practical limitation: CVS Caremark and some OptumRx pharmacy benefit contracts in Colorado have "accumulator adjustment" clauses. Under these clauses, the copay card savings do not count toward the patient's annual deductible. Patients should verify their plan documents before assuming the card eliminates all out-of-pocket exposure.

Is Compounded Dapagliflozin Legal in Colorado?

Compounded dapagliflozin is legally available to Colorado patients through state-licensed 503A compounding pharmacies in 2026. Licensed Colorado compounding pharmacies may prepare dapagliflozin formulations for an individual patient when a licensed prescriber writes a valid, patient-specific prescription.

The FDA's 503A framework (21 U.S.C. 353a) permits traditional compounding pharmacies to prepare compounds that are not commercially available in the exact form needed, or where a clinical rationale exists. Dapagliflozin does not appear on FDA's Category 1 (prohibited) or Category 2 (under review) 503B bulk drug substance lists as of mid-2025, which means 503A pharmacies in Colorado are not federally prohibited from compounding it [5].

Colorado's Pharmacy Board additionally requires that 503A pharmacies compound only for individual patient prescriptions, not in anticipation of general demand. A prescriber cannot simply call in a standing order for "compounded dapagliflozin" without a patient-specific prescription.

The cost difference is substantial. Several Colorado-based and Colorado-shipping compounding pharmacies offer dapagliflozin at $0 per month when bundled with a telehealth membership or at $30 to $80 per month as a standalone compounded prescription, compared to $620 for branded Farxiga. That price gap reflects the absence of AstraZeneca's research and marketing overhead from the compounded product's cost structure.

HealthRX Colorado Compounded Dapagliflozin Decision Framework

Use this framework when evaluating whether compounded dapagliflozin is appropriate for a specific Colorado patient:

1. Indication clarity. Confirm the patient has a documented diagnosis (T2D, HF with EF on file, or CKD with UACR and eGFR documented within 12 months).
2. Insurance pathway exhausted? Has the patient tried the AstraZeneca savings card and PA appeal for branded Farxiga? Cost should not drive the compounding decision if branded coverage is obtainable.
3. Pharmacy license verified. Confirm the compounding pharmacy holds an active Colorado Pharmacy Board license and a valid DEA registration. The Colorado Department of Regulatory Agencies (DORA) license lookup is the authoritative source.
4. Formulation confirmation. Ask the pharmacy for the Certificate of Analysis (CoA) confirming active pharmaceutical ingredient (API) identity and potency. Target: 95% to 105% of labeled potency per USP standards.
5. Monitoring plan in place. SGLT2 inhibitors require baseline renal function (eGFR), urinalysis, and periodic monitoring. A prescription without a monitoring plan is clinically incomplete regardless of the drug source.

Patients who cannot complete steps 3 through 5 should not receive compounded dapagliflozin. Bioequivalence to branded Farxiga is not tested for 503A compounds, and patients and prescribers accept that uncertainty.

Can You Get a Farxiga Prescription via Telehealth in Colorado?

Yes. Colorado law permits telehealth prescribing of dapagliflozin for new and established patients. The state follows federal DEA rules for non-controlled substances, meaning a licensed prescriber can write a Farxiga prescription after a synchronous audio-video visit without a prior in-person examination.

Colorado's telehealth parity law (C.R.S. 10-16-123) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for equivalent services. That parity applies to the visit itself. The resulting Farxiga prescription is then subject to the patient's pharmacy benefit, not the telehealth parity rule.

HealthRX's Colorado-licensed providers can evaluate patients for dapagliflozin candidacy across all three FDA-approved indications: type 2 diabetes, heart failure, and CKD. The standard intake collects fasting glucose, HbA1c, BMP (for eGFR and potassium), and a urine microalbumin or UACR result. Patients with eGFR <25 mL/min/1.73 m² are generally not candidates for dapagliflozin initiation per the Farxiga prescribing information [2].

The DAPA-CKD trial (N=4,304, published in NEJM 2020) found that dapagliflozin 10 mg daily reduced the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal/cardiovascular death by 39% relative to placebo (HR 0.61; 95% CI 0.51, 0.72; P<0.001) in patients with CKD and UACR above 200 mg/g, independent of diabetes status [6]. That result extended the indication beyond diabetes and heart failure, and Colorado telehealth providers regularly evaluate non-diabetic CKD patients for dapagliflozin candidacy.

What Is the Cheapest Way to Get Farxiga in Colorado?

The least expensive legally available path to dapagliflozin for most Colorado patients depends on insurance status.

Commercially insured Colorado patients should apply the AstraZeneca copay card first. Many pay $0 to $30 per month after the card, making branded Farxiga the cheapest option because it requires no compromise on bioequivalence.

Uninsured Colorado patients earning <600% FPL should apply to AZ&Me, AstraZeneca's patient assistance program. Processing takes two to four weeks and requires prescriber involvement, but approved patients receive Farxiga at no cost.

Uninsured Colorado patients above the AZ&Me income threshold face the starkest choice: $480 to $620 per month for branded Farxiga (with GoodRx reducing the low end), or compounded dapagliflozin at $30 to $80 per month from a licensed 503A pharmacy. The compounded route is legal and the price difference is real, but the absence of bioequivalence testing is a clinical consideration that prescriber and patient should discuss explicitly.

Colorado Medicaid patients without HF or CKD documentation should work with their provider to ensure that all qualifying comorbidities are coded accurately on the problem list. A patient who has both type 2 diabetes and stage 3 CKD (eGFR 30 to 59 mL/min/1.73 m²) with albuminuria qualifies for Medicaid coverage once the CKD is properly documented and the PA is submitted for the CKD indication rather than the diabetes indication.

GoodRx, RxSaver, and Blink Health coupons work at most Colorado retail pharmacies and do not require insurance. These programs typically yield prices of $480 to $560 per month for Farxiga 10 mg. They cannot be combined with the AstraZeneca savings card in the same transaction at most pharmacies.

Monitoring and Safety Requirements for Colorado Dapagliflozin Patients

Safe dapagliflozin prescribing requires pre-treatment and periodic laboratory monitoring regardless of whether the patient obtains branded Farxiga or a compounded formulation.

Before starting: eGFR and serum creatinine, fasting glucose or HbA1c (for T2D patients), UACR (for CKD patients), urinalysis to rule out active UTI, blood pressure, and a documented review of genital hygiene history (genital mycotic infections occur in approximately 6.9% of women and 2.7% of men treated with SGLT2 inhibitors vs. 0.9% and 0.3% placebo, per pooled trial data) [7].

At 3 months: Repeat eGFR. A mild initial drop of 5 to 10% is expected and does not require discontinuation. This reflects the drug's hemodynamic renal effect, not tubular toxicity. The FDA's prescribing label notes that dapagliflozin is not expected to be effective for glucose lowering in patients with eGFR <45 mL/min/1.73 m², though the cardiorenal benefit may persist at lower eGFR [2].

Annually: HbA1c (T2D patients), UACR (CKD patients), eGFR, blood pressure, and weight. In the DAPA-HF trial, dapagliflozin produced a mean weight reduction of 0.9 kg versus placebo at 18 months, a small but consistent signal that compounds the cardiometabolic benefit in HF patients managing fluid status [1].

Sick-day rules: Patients should hold dapagliflozin during periods of acute illness, prolonged fasting, or any procedure requiring nothing by mouth (NPO) status. Euglycemic diabetic ketoacidosis (eDKA) is rare but documented with SGLT2 inhibitors. Colorado patients on insulin or a sulfonylurea alongside dapagliflozin should receive specific instruction on eDKA symptoms: nausea, vomiting, abdominal pain, and malaise with a normal or near-normal blood glucose reading.

The 2023 ADA Standards of Medical Care in Diabetes state that "in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors for cardiovascular disease... an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or HF hospitalization" [8].

Comparing Farxiga to Other SGLT2 Inhibitors Available in Colorado

Three other SGLT2 inhibitors compete directly with Farxiga in the Colorado market in 2026: empagliflozin (Jardiance), canagliflozin (Invokana), and ertugliflozin (Steglatro).

Jardiance (empagliflozin 10 mg or 25 mg): List price approximately $600 to $630 per month in Colorado. Eli Lilly's savings programs mirror AstraZeneca's structure. The EMPEROR-Reduced and EMPEROR-Preserved trials showed cardiovascular and renal benefits comparable in magnitude to DAPA-HF. Colorado Medicaid coverage tracks Farxiga's pattern: covered for HF and CKD, not preferred for T2D.

Invokana (canagliflozin 100 mg or 300 mg): List price approximately $580 to $610 per month. The CREDENCE trial (N=4,401) showed a 30% relative reduction in the primary composite renal outcome in patients with T2D and CKD at a UACR of 300 to 5 to 000 mg/g [9]. Canagliflozin carries a black box warning for lower-extremity amputation risk (3.0 cases per 1,000 patient-years vs. 1.6 placebo in CANVAS), which influences prescriber preference, particularly in patients with peripheral arterial disease.

Steglatro (ertugliflozin): List price approximately $550 per month. Smaller evidence base. Pfizer's savings card program offers similar commercial copay relief. Colorado Medicaid coverage is more restrictive than Farxiga.

For Colorado patients with HFrEF or CKD, Farxiga and Jardiance have the strongest trial evidence and most consistent insurance coverage. For patients choosing primarily on cost, the $70 per month difference between Steglatro and Farxiga may be meaningful at cash price, though the evidence base gap is clinically relevant.